“The Bottom Is in for These 2 Stocks? Analysts Say ‘Buy’”
February 17, 2021
“Cortexyme, Inc. (CRTX)…
Overall, Cortexyme has a Moderate Buy rating from the analyst consensus, with 6 recent reviews breaking down 4 to 1 to 1, Buy-Hold-Sell. The stock’s $83.60 average price target suggests that Wall Street sees a high potential here, on the order of ~170% upside from the trading price of $30.74…
Immunovant (IMVT)…
Overall, the Strong Buy analyst consensus view on IMVT would suggest that Wall Street generally agrees with Archila’s assessment. This rating is derived from 8 recent reviews, which include 7 Buys and only a single Hold. The average price target here stands at $40.38, implying ~121% upside for the next 12 months…”
https://finance.yahoo.com/news/bottom-2-stocks-analysts-buy-163848449.html